Esperion Q3 2021 Earnings Report
Key Takeaways
Esperion reported U.S. net product revenue of $10.9 million for Q3 2021. The company is focusing on aligning its operational and expense structure for long-term growth, with the CLEAR Outcomes study on track for MACE accumulation in 2H 2022.
Announced strategic plan to align operational and expense structure.
Achieved 80% MACE accumulation in the CLEAR Outcomes Trial in October.
Continued European rollout of NILEMDO® and NUSTENDI® with partner Daiichi Sankyo.
Entered into an agreement to exchange $15 million of convertible notes for common stock.
Esperion
Esperion
Esperion Revenue by Segment
Forward Guidance
Esperion anticipates Research and Development expenses for fiscal year 2022 to be $100 to $110 million and Selling, General and Administrative expenses for fiscal year 2022 to be $120 to $130 million. Esperion expects fiscal year 2022 operating expenses to be $220 to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.
Positive Outlook
- Research and Development expenses for the full year 2021 are expected to be $110 million to $115 million.
- Selling, General and Administrative expenses for the full year 2021 are expected to be $195 million to $200 million.
- Esperion expects full-year 2021 operating expenses to be approximately $305 million to $315 million, inclusive of $25 million of non-cash, stock-based compensation.
- Research and Development expenses for fiscal year 2022 to be $100 to $110 million
- Selling, General and Administrative expenses for fiscal year 2022 to be $120 to $130 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income